|
|
|
|
Дата |
|---|
| 22.07.2026 |
| 21.07.2026 |
| 20.07.2026 |
| 17.07.2026 |
| 16.07.2026 |
| 15.07.2026 |
| 14.07.2026 |
| 13.07.2026 |
| 10.07.2026 |
| 09.07.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
2.03
|
2.07
|
2.09
|
2.01
|
2.15
|
2.05
|
|
|
1 150 119.08
|
2 339.00
|
|
2.06
|
2.14
|
2.16
|
2.05
|
2.30
|
2.10
|
|
|
1 225 262.89
|
3 412.00
|
|
2.10
|
2.20
|
2.21
|
2.10
|
2.26
|
2.12
|
|
|
340 981.33
|
1 577.00
|
|
2.05
|
2.16
|
2.09
|
2.01
|
2.21
|
2.18
|
|
|
538 494.12
|
2 223.00
|
|
2.01
|
2.06
|
2.12
|
2.03
|
2.18
|
2.05
|
|
|
239 234.14
|
953.00
|
|
2.04
|
2.09
|
2.08
|
2.04
|
2.1886
|
2.12
|
|
|
378 315.77
|
1 625.00
|
|
2.04
|
2.06
|
2.21
|
2.00
|
2.2529
|
2.09
|
|
|
786 746.15
|
2 383.00
|
|
2.17
|
2.23
|
2.25
|
2.11
|
2.49
|
2.14
|
|
|
1 257 553.01
|
2 614.00
|
|
2.15
|
2.21
|
2.49
|
2.13
|
2.50
|
2.20
|
|
|
1 122 755.51
|
2 840.00
|
|
2.43
|
2.47
|
2.84
|
2.40
|
2.917
|
2.48
|
|
|
1 801 583.41
|
3 549.00
|
Veraxa Biotech AG is a Switzerland-based company. The Company is primary engaged in biotechnology, advancing innovations in the field of antibody development and microfluidic technologies. The Company’s activities center on participating in and supporting businesses engaged in the screening of diagnostic and therapeutic antibodies, as well as their chemical or recombinant modification, formatting, validation, and preclinical and clinical development. In addition, the Company is involved in the commercialization and marketing of such solutions both domestically and internationally. The Company operates mainly through investments and strategic management of affiliated entities, providing services and oversight to companies within its portfolio.